Correlation between LRIG1 and LRIG2 expressions and expression of 11 tumor markers, with special reference to tumor suppressors, in CIN and normal cervical epithelium.

Abstract:

OBJECTIVE:Novel biological markers LRIG1 and LRIG2 have been associated with favorable as well as poor prognosis, respectively, in different cancer types, including cervical cancer. The aim of this study was to investigate possible interactions between these proteins and other tumor markers, and as diagnostic adjuncts in CIN. METHODS:Cervical biopsies from 171 women, with normal epithelium, and low-grade and high-grade CIN were stained for LRIG1 and LRIG2, and 11 additional tumor markers. The tumor markers were chosen to be relevant in cervical neoplasms. Staining was evaluated semiquantitatively. RESULTS:Expression of LRIG1 and LRIG2 was found to correlate with increasing CIN grade, as well as with expression of tumor suppressor FHIT, independent of histological grade. In addition, tumor promoter LRIG2 expression correlated negatively with expression of tumor suppressor retinoblastoma protein and positively with IL-10. The latter correlation did not however remain after adjustment for CIN grade. p53 and p16 expressions correlated positively with LRIG1 expression in univariate analyses, but significance did not hold after adjustment for CIN grade. CONCLUSION:LRIG1 and LRIG2 expressions were seen in precancerous cervical epithelium and found to increase with increasing grade. There was an association between expression of these glycoproteins and FHIT tumor suppressor protein, independently of histological grade.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Lindström AK,Asplund A,Hellberg D

doi

10.1016/j.ygyno.2011.04.049

subject

Has Abstract

pub_date

2011-08-01 00:00:00

pages

372-6

issue

2

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(11)00350-7

journal_volume

122

pub_type

杂志文章
  • Nongestational pure ovarian choriocarcinoma with contralateral teratoma.

    abstract:BACKGROUND:Nongestational pure ovarian choriocarcinoma is a rare malignancy with only 29 cases described to date. CASE:We describe a case associated with mature cystic teratoma of the contralateral ovary. Details of all 30 cases including clinical features, associations, surgicopathological findings, operative procedu...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.2000.6043

    authors: Goswami D,Sharma K,Zutshi V,Tempe A,Nigam S

    更新日期:2001-02-01 00:00:00

  • A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

    abstract:PURPOSE:Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib pr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2017.03.013

    authors: Jandial DA,Brady WE,Howell SB,Lankes HA,Schilder RJ,Beumer JH,Christner SM,Strychor S,Powell MA,Hagemann AR,Moore KN,Walker JL,DiSilvestro PA,Duska LR,Fracasso PM,Dizon DS

    更新日期:2017-05-01 00:00:00

  • A modified incision and technique for total retroperitoneal access and lymph node dissection.

    abstract::Surgical assessment of aortocaval lymph nodes in patients with unresectable primary cervical cancer helps in planning radiation treatment ports. Removal of enlarged lymph nodes may also serve a therapeutic purpose in reducing the tumor load to be sterilized by radiation. An extraperitoneal dissection is considered to ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1995.1036

    authors: Vasilev SA

    更新日期:1995-02-01 00:00:00

  • Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG.

    abstract:OBJECTIVE:Hyperglycosylated hCG (hCG-H) is a glycosylation variant of hCG produced by cytotrophoblast cells at implantation of pregnancy and in choriocarcinoma. We investigated the biological function of hCG-H in invasion in vitro and in vivo and the use of hCG-H antibodies in blocking tumorigenesis and cancer growth i...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.12.047

    authors: Cole LA,Dai D,Butler SA,Leslie KK,Kohorn EI

    更新日期:2006-08-01 00:00:00

  • Abnormal cervical cytology leading to the diagnosis of gastric cancer.

    abstract::There have been nine cases reported in the English literature in which the finding of malignant cells on cervical/vaginal cytology led to the diagnosis of primary gastric cancer. We report on a patient with gastric carcinoma, metastatic to the cervix, in which the diagnosis was suspected by the finding of signet ring ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/0090-8258(90)90117-4

    authors: McGill F,Adachi A,Karimi N,Wadler S,Kim ES,Greston WM,Kleiner GJ

    更新日期:1990-01-01 00:00:00

  • The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.

    abstract:OBJECTIVES:CD4(+)CD25(+) regulatory T-cells (Tregs), that express the transcription factor FOXP3, suppress effector T-cell populations and can enable tumour cells to evade the host immune response. In this study, we investigated the numbers of FOXP3(+) Tregs in the normal and malignat endometrium and examined potential...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.04.021

    authors: Giatromanolaki A,Bates GJ,Koukourakis MI,Sivridis E,Gatter KC,Harris AL,Banham AH

    更新日期:2008-08-01 00:00:00

  • Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.

    abstract:OBJECTIVES:Surgical resection of enlarged cardiophrenic lymph nodes (CPLNs) in primary treatment of advanced ovarian cancer has not been widely studied. We report on a cohort of patients undergoing CPLN resection during primary cytoreductive surgery (CRS), examining its feasibility, safety, and potential impact on clin...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2017.09.001

    authors: Cowan RA,Tseng J,Murthy V,Srivastava R,Long Roche KC,Zivanovic O,Gardner GJ,Chi DS,Park BJ,Sonoda Y

    更新日期:2017-11-01 00:00:00

  • Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation.

    abstract:OBJECTIVE:Protease-activated receptor-2 (PAR-2) is a G-protein-coupled receptor that is cleaved and activated by trypsin and tryptase. There is evidence that PAR-2 contributes to tumor progression in stomach, colon, pancreas, prostate and breast cancer patients. However, the role of PAR-2 in cervical cancer is still un...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2007.08.083

    authors: Sánchez-Hernández PE,Ramirez-Dueñas MG,Albarran-Somoza B,García-Iglesias T,del Toro-Arreola A,Franco-Topete R,Daneri-Navarro A

    更新日期:2008-01-01 00:00:00

  • Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?

    abstract:OBJECTIVES:Lymphovascular space invasion (LVSI) is an independent risk factor for recurrence and poor survival in early-stage endometrioid endometrial cancer (EEC), but optimal adjuvant treatment is unknown. We aimed to compare the survival of women with early-stage EEC with LVSI treated postoperatively with observatio...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2019.12.028

    authors: Beavis AL,Yen TT,Stone RL,Wethington SL,Carr C,Son J,Chambers L,Michener CM,Ricci S,Burkett WC,Richardson DL,Staley AS,Ahn S,Gehrig PA,Torres D,Dowdy SC,Sullivan MW,Modesitt SC,Watson C,Veade A,Ehrisman J,Havril

    更新日期:2020-03-01 00:00:00

  • Immunohistochemical detection of somatostatin receptors in human ovarian tumors.

    abstract:OBJECTIVE:It is well established that many human tumors can express somatostatin receptors. This is the molecular basis for the application of long-acting somatostatin analogues for therapeutic and diagnostic purposes. However, there are discrepancies in earlier studies regarding the prevalence of somatostatin receptor...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2001.6468

    authors: Schulz S,Schmitt J,Quednow C,Roessner A,Weise W

    更新日期:2002-02-01 00:00:00

  • Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia.

    abstract:OBJECTIVE:To evaluate testing for high-risk human papillomavirus (HR HPV) E6/E7 mRNA transcripts 6 months after conisation for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) to determine the risk of residual CIN2+. METHODS:We prospectively followed 344 women treated for CIN2+ by conisation. HR HPV mRNA te...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.07.032

    authors: Tropé A,Jonassen CM,Sjøborg KD,Nygård M,Dahl FA,Alfsen GC,Lie AK

    更新日期:2011-11-01 00:00:00

  • Malignant struma ovarii with Graves' disease.

    abstract:BACKGROUND:Malignant struma ovarii is a rare tumor, consisting of a struma ovarii with malignant change. Because of the rarity of the tumor, only a few reports with detailed data of thyroid function of the patient have been published. CASE:Medical and surgical treatments were performed in a case of malignant struma ov...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.2000.5966

    authors: Kano H,Inoue M,Nishino T,Yoshimoto Y,Arima R

    更新日期:2000-12-01 00:00:00

  • Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.

    abstract:OBJECTIVE:Although the epidemiology of typical endometrial carcinomas (grades 1-2 endometrioid or Type I) is well established, less is known regarding higher grade endometrioid or non-endometrioid carcinomas (Type II). Within a large Gynecologic Oncology Group trial (GOG-210), which included central pathology review, w...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2013.02.023

    authors: Brinton LA,Felix AS,McMeekin DS,Creasman WT,Sherman ME,Mutch D,Cohn DE,Walker JL,Moore RG,Downs LS,Soslow RA,Zaino R

    更新日期:2013-05-01 00:00:00

  • Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.

    abstract:OBJECTIVE:To compare the frequencies of somatic homologous recombination (HR) gene mutations identified in next-generation sequencing (NGS) genomic profiling of uterine serous carcinomas (USCs) and high-grade serous ovarian carcinomas (HGSOCs). METHODS:Data for this analysis was obtained from AACR Project GENIE, a mul...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.08.012

    authors: Wallbillich JJ,Morris RT,Ali-Fehmi R

    更新日期:2020-11-01 00:00:00

  • Outcome of investigations for postmenopausal vaginal bleeding in women under the age of 50 years.

    abstract:OBJECTIVE:The objective of this study is to determine the incidence of endometrial cancer in young postmenopausal women presenting with vaginal bleeding. METHODS:Cross-sectional study of postmenopausal women presenting with vaginal bleeding in a gynaecological oncology centre in the United Kingdom. All women underwent...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2011.12.453

    authors: Burbos N,Musonda P,Crocker SG,Morris EP,Duncan TJ,Nieto JJ

    更新日期:2012-04-01 00:00:00

  • Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma.

    abstract::CA125 and CA19-9 levels were serially evaluated in blood samples from 21 patients during and after integrated surgical and chemotherapeutic treatment for ovarian carcinoma. Serial measurement of CA125 and CA19-9 correlated with clinical course of disease in 89.7 and 72.7% of instances, respectively. The decrease of se...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(87)90173-9

    authors: Fioretti P,Gadducci A,Ferdeghini M,Bartolini T,Bianchi R,Facchini V

    更新日期:1987-11-01 00:00:00

  • Gynecologic oncology providers endorse practice-changing impact of communication skills training.

    abstract:OBJECTIVE:Effective communication improves patient outcomes and is crucial to good patient care. Communication skills training (CST) has been shown to improve communication skills in non-gynecologic oncology specialties. We sought to develop and test CST for gynecologic oncology (GO) providers. METHODS:We developed an...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.03.242

    authors: Lefkowits C,Bevis K,Carey EC,Sheeder J,Arnold RM,Podgurski L

    更新日期:2019-06-01 00:00:00

  • High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.

    abstract::From September 1986 to November 1988, 38 patients with previously untreated ovarian cancer, FIGO stages III and IV, were allocated to a study testing the efficacy of high-dose platinum delivered as combined carboplatin and cisplatin. The regimen was as follows: Day 1, 250-350 mg/m2 carboplatin and 500 mg/m2 cyclophosp...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章

    doi:10.1016/0090-8258(92)90016-c

    authors: Bertelsen K,Bastholt L

    更新日期:1992-01-01 00:00:00

  • Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy.

    abstract:OBJECTIVE:Debate continues about optimal management of patients with node-positive stage I cervical cancer. Our objective was to determine if patient outcomes are affected by radical hysterectomy in the modern era of adjuvant chemoradiation. METHODS:Cervical cancer patients diagnosed from 2000 to 2008 were identified....

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2012.03.046

    authors: Ziebarth AJ,Smith H,Killian ME,Nguyen NA,Durst JK,Subramaniam A,Kim KH,Leath CA 3rd,Straughn JM Jr,Alvarez RD

    更新日期:2012-07-01 00:00:00

  • Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.

    abstract:OBJECTIVE:Preoperative differentiation of primary and metastatic ovarian tumors is difficult. Young age of the patient, bilateralism and reduced multilocularity are cited characteristics of secondary ovarian malignancies. We sought to identity pre- and perioperative factors which may aid in differentiating metastatic o...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.09.046

    authors: Antila R,Jalkanen J,Heikinheimo O

    更新日期:2006-04-01 00:00:00

  • Role of microRNAs in drug-resistant ovarian cancer cells.

    abstract:OBJECTIVES:Chemotherapy is the preferred therapeutic approach for the therapy of advanced ovarian cancer, but a successful long-term treatment is prevented by the development of drug resistance. Recent works have underlined the involvement of non-coding RNAs, microRNAs (miRNAs) in cancer development, with several conje...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2008.08.017

    authors: Sorrentino A,Liu CG,Addario A,Peschle C,Scambia G,Ferlini C

    更新日期:2008-12-01 00:00:00

  • A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.

    abstract:OBJECTIVE:To assess the safety and efficacy of pegylated liposomal doxorubicin (PLD), carboplatin, plus bevacizumab in patients with ovarian, fallopian tube, or primary peritoneal cancer. METHODS:Patients with platinum-sensitive, recurrent disease received PLD 30 mg/m(2) and carboplatin area under the curve (AUC) 5 on...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2012.05.028

    authors: del Carmen MG,Micha J,Small L,Street DG,Londhe A,McGowan T

    更新日期:2012-09-01 00:00:00

  • Decreased expression of the CDK inhibitor p27Kip1 and increased oxidative DNA damage in the multistep process of cervical carcinogenesis.

    abstract:OBJECTIVE:The expression of the CDK inhibitor p27Kip1 and the extent of endogenous oxidative DNA damage were evaluated in the multistep cervical carcinogenesis. METHODS:Archival specimens of low-grade (L) squamous intraepithelial lesions (SILs) (n=32), high-grade (H) SILs (n=24) and invasive carcinomas (n=48) of the c...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2003.12.008

    authors: Sgambato A,Zannoni GF,Faraglia B,Camerini A,Tarquini E,Spada D,Cittadini A

    更新日期:2004-03-01 00:00:00

  • Adjuvant chemotherapy does not improve disease-free survival in FIGO stage IC ovarian granulosa cell tumors: The MITO-9 study.

    abstract:OBJECTIVE:Evidence-based management of granulosa cell tumors of the ovary (GCT) has been not yet standardized: surgery, including fertility-sparing procedures for young women, has been traditionally the standard treatment; on the other hand, chemotherapy has been used for treatment of advanced and/or recurrent disease....

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2016.08.316

    authors: Mangili G,Ottolina J,Cormio G,Loizzi V,De Iaco P,Pellegrini DA,Candiani M,Giorda G,Scarfone G,Cecere SC,Frigerio L,Gadducci A,Marchetti C,Ferrandina G

    更新日期:2016-11-01 00:00:00

  • Choriocarcinoma in a term placenta with maternal metastases.

    abstract::Choriocarcinoma of the nonmolar placenta is presumptively a rare entity and is usually associated with widespread maternal metastases at the time of diagnosis. Nonmetastatic disease goes unrecognized and undiagnosed because placental carcinoma can be limited to a few villi, and grossly evident disease is often misinte...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/0090-8258(92)90264-j

    authors: Christopherson WA,Kanbour A,Szulman AE

    更新日期:1992-08-01 00:00:00

  • The role of cancer antigen 125 (CA 125) in the management of ovarian epithelial carcinomas.

    abstract::From June 1, 1984, to May 31, 1985, 98 cases of epithelial ovarian carcinomas were assessed and followed prospectively using a new murine monoclonal antibody OC 125 which detects the antigen CA 125. Serous tumors comprised 43.7% of cases, mucinous tumors 20.4%, endometrioid tumors 16%, and other epithelial tumors 19.4...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(88)90042-x

    authors: Altaras MM,Goldberg GL,Levin W,Bloch B,Darge L,Smith JA

    更新日期:1988-05-01 00:00:00

  • Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

    abstract::The incidence of endometrial cancer (EC) in the U.S. has been rising, from an estimated annual incidence of 49,560 in 2013 to 61,380 in 2017. Meanwhile, the SEER-based relative survival of women with EC in the U.S. has remained flat [82.3% from 1987 to 1989, 82.8% from 2007 to 2013] and our recent increased understand...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2018.02.005

    authors: Lheureux S,McCourt C,Rimel BJ,Duska L,Fleming G,Mackay H,Mutch D,Temkin SM,Lynn J,Kohn EC

    更新日期:2018-02-22 00:00:00

  • The Patient Protection and Affordable Care Act: what every provider of gynecologic oncology care should know.

    abstract::The Patient Protection and Affordable Care Act (ACA) was signed into law by President Barack Obama in 2010. While initial implementation of the law began shortly thereafter, the full implementation will take place over the next few years. With respect to cancer care, the act was intended to make care more accessible, ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2013.02.036

    authors: Duska LR,Engelhard CL

    更新日期:2013-06-01 00:00:00

  • Overall survival after pelvic exenteration for gynecologic malignancy.

    abstract:BACKGROUND:Five-Year survival after pelvic exenteration for gynecologic malignancies has been reported as high as 60%. The objective of this study was to determine overall survival (OS) after pelvic exenteration and evaluate factors impacting outcome. METHODS:A retrospective review of all women who underwent pelvic ex...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2014.06.034

    authors: Westin SN,Rallapalli V,Fellman B,Urbauer DL,Pal N,Frumovitz MM,Ramondetta LM,Bodurka DC,Ramirez PT,Soliman PT

    更新日期:2014-09-01 00:00:00

  • A longitudinal study of antigen expression in epithelial ovarian cancer.

    abstract::The extent to which the antigenic phenotype of human epithelial ovarian cancer changes during the course of the disease is an issue that must be addressed in order to maximize the potential of antibody-directed imaging and therapy. We have obtained tumor specimens at two separate operations from ten patients with epit...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90179-0

    authors: Rubin SC,Finstad CL,Hoskins WJ,Federici MG,Lloyd KO,Lewis JL Jr

    更新日期:1989-09-01 00:00:00